Suloctidil in patients with recent thromboembolic stroke

Completed

Phase N/A Results

Summary of Purpose

To determine whether suloctidil would influence the subsequent recurrence of stroke, the occurrence of myocardial infarction, or cardiovascular death in patients suffering previously from thromboembolic stroke.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 1 March 2001.

Unavailable Unavailable Unavailable Unavailable Unavailable Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Sponsors

  • Continental Pharma, Belgium.

Trial Design

Randomized, double-blind, placebo-controlled trial of 438 patients at 4 centers.

Contacts

Not available